|
|
| SPEAKER |
| Geoff MacKay |
| President and CEO |
|
Organogenesis
|
|
|
MEETING
|
|
May 2009 |
|
| BIOGRAPHY |
Geoff MacKay has served as President and CEO at Organogenesis Inc. (Canton, Massachusetts) since 2003. Geoff provides Organogenesis with significant global commercial experience spanning the pharmaceutical and biotechnology sectors. He has held numerous leadership positions within Novartis AG in roles such as Vice-President & Business Unit Head, Transplantation & Immunology at Novartis Canada, Vice-President of Tissue-Engineering in Novartis USA, Head of Global Sales Immunology & Transplantation based in Basel, Switzerland, and prior to that as Sales & Marketing Manager of Novartis Biotech Europe. Geoff has been specifically involved in the emerging field of regenerative medicine for the last decade.
|
| TALK |
|
Commercialisation of Living Cell Therapies to Induce Soft Tissue Regeneration
|
| DESCRIPTION |
|
Organogenesis Inc is a regenerative medicine company that has a focus in developing cell therapies that induce soft tissue regeneration for multiple applications. The company has served as an early pioneer in the field and has gradually developed competencies in characterisation and amplification of allogeneic cells, mass-production of cell therapies and multiple aspects of commercialising living technologies. The mission of the company is to help make regenerative medicine a standard-of-care choice for patients who deserve it. Many of the challenges that have been faced and addressed along the development pathway will be discussed. To date the company has treated well over 200,000 patients with its tissue-engineered products. New clinical data will be presented that further highlight the utility of delivering living, allogeneic cell therapies to induce soft tissue regeneration.
|
|
